Credit Suisse Starts Akebia Therapeutics (AKBA) at Outperform
Tweet
Share
E-mailGet Alerts AKBA Hot Sheet
Price: $0.89 --0%
Rating Summary:
13 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 4 | Down: 10 | New: 25
Rating Summary:
13 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 4 | Down: 10 | New: 25
Join SI Premium – FREE
Credit Suisse initiated coverage on Akebia Therapeutics (NASDAQ: AKBA) with an Outperform rating and a price target of $25.00.
For an analyst ratings summary and ratings history on Akebia Therapeutics click here. For more ratings news on Akebia Therapeutics click here.
Shares of Akebia Therapeutics closed at $16.86 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Canaccord Starts First Tracks Biotherapeutics (TRAX) at Buy
- Stephens Starts Smithfield Foods (SFD) at Equal Weight
- BofA Securities Reinstates Mouwasat (4002:AB) at Underperform
Create E-mail Alert Related Categories
New CoverageRelated Entities
Credit SuisseSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
